A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors.

Authors

Kyriakos P. Papadopoulos

START San Antonio, San Antonio, TX

Kyriakos P. Papadopoulos , Manish Sharma , Reinhard Dummer , Esteban Rodrigo Imedio , Marie-Laurence Yge , Sandrine Micallef , Anne Bellon , Anastasios Stathis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.

First Author: Hans Gelderblom

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRAS^G12C inhibitor, in advanced solid tumors.

First Author: Yan Zhang

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.

First Author: Kaiwen Li

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.

First Author: Ramaswamy Govindan